Glenmark Pharmaceuticals has informed that it attached media release titled ‘Glenmark Pharma Expands Cardiometabolic Portfolio with the Launch of Empagliflozin and its Fixed-Drug Combinations in India’.
The above information is a part of company’s filings submitted to BSE.